A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Latest Information Update: 04 Jan 2022
At a glance
- Drugs Concizumab (Primary) ; Turoctocog alfa
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms Explorer 5
- Sponsors Novo Nordisk
- 14 Dec 2021 Results (N=61) from phase 2 trials explorer4 (NCT03196284) and explorer5 (NCT03196297) describing surgeries and diagnostic procedures presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results of an exploratory pooled analyses (of explorer4 (NCT03196284) and explorer5 (NCT03196297) phase 2 trials) assessing changes in HRQoL after long-term concizumab treatment presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 30 May 2021 This trial has been completed in Spain, according to European Clinical Trials Database record.